ABOUT

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna..

PHILOSOPHY OF THE MANAGEMENT

In addition to the development and production of standard generic products, the philosophy of the management is to bring innovative solutions to the development of new products, in order to add value to our customers’ business.

In this respect, Rivopharm has expanded its product development capabilities to capitalize on the latest advances in product formulation and delivery technologies.

HISTORY

1961

Rivopharm was founded focusing its attention especially on the Swiss market, specializing in branded and generic pharmaceutical products.

1980

Activities shift to mass production and Rivopharm supplies UNICEF and various International Humanitarian Organizations and Ministries of Health. Rivopharm invests in new equipment and technology to achieve quality, capability and efficiency.

1990

Rivopharm expands its business in several countries of the former Soviet Union.

1998

Refocus of activities to development and manufacture of generic products for European markets.

2003

Significant investments are made to upgrade the production facilities to the latest cGMP standards. Rivopharm operates in a renovated plant, located in Manno, near Lugano.

2005

Change of ownership of the company. Rivopharm is in partnership with many of Europe’s leading generics companies allowing for more important investments.

2008

Increased production and packaging capacity by acquiring new equipment at all levels in the factory.

2009

Large investment in modern technologies for Research and Development both in formulation and analytics.

2010

Conclusion of several regulatory procedures at National and DCP level, including the first ever registration of Nicorandil tablets as generic product in some European countries.

2011

First company to launch generic Nicorandil tablets in EU markets.

2012

Successfully completed the registration dossier for Lacidipine tablets 2 mg, 4 mg and 6 mg. First ANDA filing scheduled for 2012.

2013

Another exciting development concluded: Racecadotril capsules 100 mg; Opening of the representative office in London, UK for direct marketing of the products.

2014

Historic achievement of passing FDA inspection with no 483’s.

2015

First company to launch generic Racecadotril capsules.

2016

Acquisition of Holsten Pharma, the new German affiliate of Rivopharm Group; In early 2016 Rivopharm SA obtained ANDA’s approval for 2 products.

2017

Acquisition of Sanoswiss, the new affiliate of Rivopharm Group in Baltics. Launch of two generic products in US. Acquisition of a basket of 77 molecules from Teva

2018

Start of direct marketing in Austria, Hungary and Poland

accross
the globe

MARKETS

Rivopharm has registered and is selling, directly and through its customers, generic products in over 50 countries across the globe, from Australia to North America.

DOCUMENTS
AND CERTIFICATES

Dun & Bradstreet Rating Certificate

Certificate of GMP Compliance

Manufacturing Authorization - Swissmedic (Original - Italian)

GET IN TOUCH WITH
OUR TEAM OF EXPERTS AT: